Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination

References

• Burgdorf, SK, Nielsen, HJ, Rosenberg, J. Immunotherapy in colorectal cancer. Scand J Gastroenterol 2008.
   Google Scholar
• Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 2006; 12: 3064–9
   PubMed Web of Science ®Google Scholar
• Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004; 53: 275–306
   PubMed Web of Science ®Google Scholar
• Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol 2005; 16: 847–62
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D. Systemic treatment of colorectal cancer. Eur J Cancer 2002; 38: 1000–15
   PubMed Web of Science ®Google Scholar
• Goldberg RM. Advances in the treatment of metastatic colorectal cancer. Oncologist 2005; 10(Suppl 3)40–8
   PubMed Web of Science ®Google Scholar
• Zampino MG, Magni E, Massacesi C, Zaniboni A, Martignetti A, Zorzino L, et al. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer 2007; 110: 752–8
   PubMedGoogle Scholar
• Ju JH, Chang SC, Wang HS, Yang SH, Jiang JK, Chen WC, et al. Changes in disease pattern and treatment outcome of colorectal cancer: A review of 5,474 cases in 20 years. Int J Colorectal Dis 2007; 22: 855–62
   PubMed Web of Science ®Google Scholar
• Arndt V, Merx H, Stegmaier C, Ziegler H, Brenner H. Restrictions in quality of life in colorectal cancer patients over three years after diagnosis: A population based study. Eur J Cancer 2006; 42: 1848–57
   PubMed Web of Science ®Google Scholar
• McWilliams RR, Goetz MP, Morlan BW, Salim M, Rowland KM, Krook JE, et al. Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Clin Colorectal Cancer 2007; 6: 516–21
   PubMedGoogle Scholar
• Nakata B, Sowa M, Tsuji A, Kamano T, Sasaki K, Fukunaga Y, et al. Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study. J Exp Clin Cancer Res 2007; 26: 51–60
   PubMedGoogle Scholar
• Nagorsen D, Scheibenbogen C, Thiel E, Keilholz U. Immunological monitoring of cancer vaccine therapy. Expert Opin Biol Ther 2004; 4: 1677–84
   PubMed Web of Science ®Google Scholar
• Duffy MJ, van DA, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43: 1348–60
   PubMed Web of Science ®Google Scholar
• Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313–27
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002; 8: 156–64
   PubMed Web of Science ®Google Scholar
• Moller SN, Vejgaard SI, Ornbjerg WS, Schrohl AS, Dowell B, Davis G, et al. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol 2008; 43: 774–86
   PubMedGoogle Scholar
• Burgdorf SK, Fischer A, Claesson MH, Kirkin AF, Dzhandzhugazyan KN, Rosenberg J. Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: Report from a phase I study. J Exp Clin Cancer Res 2006; 25: 201–6
   PubMed Web of Science ®Google Scholar
• Burgdorf SK, Fischer A, Myschetzky PS, Munksgaard SB, Zocca MB, Claesson MH, et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol Rep 2008; 20: 1305–11
   PubMed Web of Science ®Google Scholar
• Dupont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: Determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol 2005; 66: 175–91
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999; 80: 495–503
   PubMed Web of Science ®Google Scholar
• Huang H, Hao S, Li F, Ye Z, Yang J, Xiang J. CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology 2007; 120: 148–59
   PubMed Web of Science ®Google Scholar
• Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11–22
   PubMed Web of Science ®Google Scholar
• Nembrini C, Abel B, Kopf M, Marsland BJ. Strong TCR signaling, TLR ligands, and cytokine redundancies ensure robust development of type 1 effector T cells. J Immunol 2006; 176: 7180–8
   PubMedGoogle Scholar
• Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest 2007; 117: 1119–27
   PubMed Web of Science ®Google Scholar
• Moingeon P. Strategies for designing vaccines eliciting Th1 responses in humans. J Biotechnol 2002; 98: 189–98
   PubMed Web of Science ®Google Scholar
• Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H, Sekimoto M, et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 2000; 46(Suppl)S52–S61
   PubMedGoogle Scholar
• Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE(6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002; 196: 619–28
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott JB, Todryk SM, Dalgleish AG. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother 2002; 51: 521–31
   PubMed Web of Science ®Google Scholar
• Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: Decisions between life and death. Int J Biochem Cell Biol 2007; 39: 1462–75
   PubMed Web of Science ®Google Scholar
• van HR, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11: 397–408
   PubMed Web of Science ®Google Scholar
• Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75: 163–89
   PubMed Web of Science ®Google Scholar
• Collins HM, Morris TM, Watson SA. Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: Relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. Br J Cancer 2001; 84: 1664–70
   PubMedGoogle Scholar
• Wagenaar-Miller RA, Gorden L, Matrisian LM. Matrix metalloproteinases in colorectal cancer: Is it worth talking about?. Cancer Metastasis Rev 2004; 23: 119–35
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Hansen U, Brunner N, Nielsen HJ, Illemann M, Nielsen BS. Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer 2005; 113: 198–206
   PubMed Web of Science ®Google Scholar
• Nielsen HJ, Christensen IJ, Brunner NA. Serological markers of colorectal cancer]. Ugeskr Laeger 2005; 167: 4163–7
   PubMedGoogle Scholar
• Ferroni P, Palmirotta R, Spila A, Martini F, Formica V, Portarena I, et al. Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer. Oncology 2006; 71: 176–84
   PubMedGoogle Scholar
• Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol 2008; 15: 3433–9
   PubMedGoogle Scholar
• Kosmider, S, Stella, DL, Field, K, Moore, M, Ananda, S, Oakman, C, , et al. Preoperative investigations for metastatic staging of colon and rectal cancer across multiple centres – what is current practice?. Colorectal Dis 2008.
   Google Scholar
• Tan, E, Gouvas, N, Nicholls, RJ, Ziprin, P, Xynos, E, Tekkis, PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 2008.
   PubMedGoogle Scholar
• Hilska M, Roberts PJ, Collan YU, Laine VJ, Kossi J, Hirsimaki P, et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 2007; 121: 714–23
   PubMedGoogle Scholar
• Kim TD, Song KS, Li G, Choi H, Park HD, Lim K, et al. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 2006; 6: 211
   PubMed Web of Science ®Google Scholar
• Hammer JH, Basse L, Svendsen MN, Werther K, Brunner N, Christensen IJ, et al. Impact of elective resection on plasma TIMP-1 levels in patients with colon cancer. Colorectal Dis 2006; 8: 168–72
   PubMed Web of Science ®Google Scholar
• Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000; 20(2B)1085–91
   PubMedGoogle Scholar
• Nielsen HJ, Brunner N, Frederiksen C, Lomholt AF, King D, Jorgensen LN, et al. Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): A novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection. Scand J Gastroenterol 2008; 43: 242–8
   PubMed Web of Science ®Google Scholar
• Sorensen NM, Bystrom P, Christensen IJ, Berglund A, Nielsen HJ, Brunner N, et al. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 2007; 13: 4117–22
   PubMed Web of Science ®Google Scholar